Novo Nordisk to Slash U.S. List Prices for Semaglutide Portfolio from 2027 Amid Rising Competitive Pressure
Novo Nordisk Semaglutide Price Cut 2027: Wegovy & Ozempic List Price Drops to $675 Amid Eli Lilly Zepbound Competition Novo Nordisk announced that it will cut the U.S. list price of its leading semaglutide‑based medicines, Wegovy, Ozempic, and Rybelsus, to $675 per month starting January 2027, marking a significant step to improve affordability and access to GLP‑1 therapies for obesity and type 2 diabetes The price reduction, representing up to 50% off for Wegovy and 35% for
Top 10 Pharmaceutical Companies by Revenue 2025: Best-Selling Drugs Analysis | iPharmaCenter
Top pharmaceutical companies by revenues in 2025. The revenues are captured from the official websites of pharmaceutical companies
CagriSema misses non‑inferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% | iPharmaCenter
CagriSema produced large absolute weight loss in REDEFINE 4 but failed its main goal of matching Eli Lilly’s tirzepatide, raising questions about its competitive positioning in obesity. CagriSema delivers strong weight loss, but not enough vs tirzepatideIn the open‑label phase 3 REDEFINE 4 trial, adults with obesity and at least one comorbidity were randomized to once‑weekly CagriSema (fixed‑dose cagrilintide 2.4 mg plus semaglutide 2.4 mg) or tirzepatide 15 mg, both given su
Novartis Advances Remibrutinib Toward FDA Approval in Chronic Inducible Urticaria | iPharmaCenter
Does Novartis remibrutinib work for chronic inducible urticaria? Yes, first Phase III success in 3 CIndU types Oral remibrutinib hit primary endpoint vs. placebo at week 12 in RemIND trial, with complete responses in symptomatic dermographism, cold urticaria, and cholinergic urticaria. Rhapsido CIndU approval status Novartis seeks FDA approval for dermographism (most common form of CIndU). Why This Matters First targeted therapy for CIndU, affecting ~29M adults worldwide Sa
Lilly's Taltz + Zepbound Combo Achieves Superior Psoriasis Clearance and Weight Loss in Phase 3b Trial | iPharmaCenter
Eli Lilly shared encouraging early findings from the innovative TOGETHER-PsO trial, testing ixekizumab (Taltz) alongside tirzepatide (Zepbound) against ixekizumab solo in patients facing moderate-to-severe plaque psoriasis plus obesity or excess weight and related health issues. Trial Achieves Dual Goals After 36 weeks, those getting both drugs saw far better outcomes on the main goal, full skin clearing (PASI 100 score) paired with 10%+ body weight drop, outpacing the ixekiz
Amgen’s Uplizna wins European Commission approval for generalized myasthenia gravis | iPharmaCenter
Amgen has secured European Commission clearance for Uplizna (inebilizumab) as an add‑on therapy for adults with generalized myasthenia gravis (gMG) who test positive for anti‑acetylcholine receptor (AChR) or anti‑muscle‑specific tyrosine kinase (MuSK) antibodies. The decision introduces a targeted B‑cell–depleting option that can be given as two loading infusions followed by maintenance dosing twice a year, with the aim of providing sustained disease control alongside existin